BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Panacos Pharmaceuticals Inc. 

209 Perry Parkway
Suite 7
Gaithersburg  Maryland  20877  U.S.A.
Phone: 240-631-1395 Fax: 301-208-8755


SEARCH JOBS

Panacos Pharmaceuticals Inc. is developing the next generation of anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. HIV infects approximately 1.7 million people in North America and Western Europe and approximately 40 million people worldwide. Approximately 650,000 patients are treated annually for HIV in the United States and Western Europe. Resistance to currently available drugs is one of the most pressing problems in HIV therapy and the leading cause of treatment failure. Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.

Panacos' lead candidate, bevirimat (PA-457), is the first in a new class of oral HIV therapeutics under development called maturation inhibitors, discovered by Panacos scientists and their academic collaborators. Based on its novel mechanism of action, bevirimat is designed to have potent activity against a broad range of HIV, including strains that are resistant to existing classes of drugs. The Company has completed seven clinical studies of bevirimat in over 300 subjects, showing significant reductions in viral load in HIV-infected subjects and a promising safety profile, and is currently in Phase 2b clinical trials.

The US Food and Drug Administration (FDA) has granted Fast Track designation to bevirimat. Fast Track is a process designed to expedite development and approval of new drugs that may have the potential to improve treatment for serious or life-threatening diseases. Developers of Fast Tracked products have greater access to FDA resources as well as eligibility for rolling NDA submissions. In addition, Fast Track designation may enable priority FDA review and accelerated approval.

In addition to bevirimat, Panacos is developing second generation maturation inhibitors and small molecule inhibitors of HIV fusion.

Last Updated: 11-17-2006

 Key Statistics


Email:
Ownership: Public

Web Site: Panacos Pharmaceuticals Inc.
Employees: 40
Symbol: PANC
 



Industry
Pharmaceutical






 Company News
Panacos Pharmaceuticals Inc. (PANC) to Report Third Quarter Results and Provide Development Update 10/28/2008 10:42:42 AM    More...
Panacos Pharmaceuticals Inc. (PANC) Names New CFO 1/7/2008 6:35:18 AM    More...
Panacos Pharmaceuticals Inc. (PANC) Announces Greater than 1 Log10 Mean Reduction in 300 mg Bevirimat Cohort 10/26/2007 12:01:41 PM    More...
Panacos Pharmaceuticals Inc. (PANC) to Report Third Quarter Results for 2007 10/19/2007 11:42:02 AM    More...
Panacos Pharmaceuticals Inc. (PANC) Extends Medicinal Chemistry Contract With Evotec AG (EVTG.F) Into Fourth Year and Expands Into Development Chemistry 5/10/2007 10:57:11 AM    More...
Panacos Pharmaceuticals Inc. (PANC) Appoints Alan W. Dunton, M.D. As New CEO 1/8/2007 11:04:47 AM    More...

//-->